Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.69 |
| ▸ | NPY4R | P50391 | 8/20 | 0.69 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.69 |
| ▸ | NPY1R | P25929 | 6/20 | 0.69 |
| ▸ | TFPI | P10646 | 4/20 | 0.69 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.68 |
| ▸ | CALCR | P30988 | 3/20 | 0.68 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.68 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.68 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.68 |
| ▸ | GLP1R | P43220 | 2/20 | 0.66 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905167 | 0.94 | CALCR (0.76) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29720295 | 0.92 | CALCR (0.73) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL4331434 | 0.91 | NPY2R (0.75) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL15669203 | 0.90 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL9979655 | 0.89 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30299016 | 0.89 | CALCR (0.69) | RAMP3CALCRRAMP1RAMP2CALCRL | |
| SCHEMBL29519841 | 0.88 | CALCR (0.71) | RAMP3CALCRRAMP1RAMP2CALCRL | |
| SCHEMBL15669269 | 0.88 | NPY2R (0.76) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30574250 | 0.88 | NPY2R (0.72) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29436010 | 0.88 | NPY2R (0.77) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3667 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031677-A | Leptin receptor agonist antibodies for the treatment of metabolic dysfunction or hypoleptinemia | 瑞泽恩制药公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122005762-A | Tenipotene oral self-emulsifying preparation and preparation method thereof | 深圳翰宇药业股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4734978-A2 | COMBINATION THERAPIES USING PSILOCYBIN | University of Padova (IT) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090520-A1 | METHOD OF PREVENTING MUSCLE LOSS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | claimed |
| US-12605354-B2 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions | NEW FRONTIER LABS, LLC (US) | 2026-04-21 | — | — | US | claimed |
| US-20260102473-A1 | NOVEL FORMULATIONS | ARECOR LTD (GB) | 2026-04-16 | — | — | US | claimed |
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | claimed |
| US-20260091086-A1 | POLYPEPTIDE COMBINATIONS AND USES THEREOF | MEDIMMUNE LTD (GB) | 2026-04-02 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| WO-2022066212-A1 | A LONG-LASTING GLP1 ANALOGUE DRUG FOR TYPE-2 DIABETES | WEI YANG (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2022060827-A2 | USE OF LEPR AGONISTS FOR PAIN | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | claimed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| CN-107921094-B | IGFBP3 and uses thereof | 圣拉斐尔医院有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114127105-A | Anti-metallothionein antibodies and uses thereof | 康涅狄格大学 | 2022-03-01 | — | — | CN | claimed |
| WO-2022040035-A1 | TREATMENT OF OBESITY IN SUBJECTS HAVING VARIANT NUCLEIC ACID MOLECULES ENCODING CALCITONIN RECEPTOR (CALCR) | REGENERON PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | claimed |
| EP-3658115-B1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR | ADOCIA (FR) | 2022-02-23 | — | — | EP | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
| EP-3956259-A1 | CO-FORMULATIONS OF AMYLIN ANALOGUES WITH INSULIN ANALOGUES FOR TREATMENT OF DIABETES | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-02-23 | — | — | EP | claimed |
| CN-114026107-A | Production of disulfide peptides | 巴克姆股份公司 | 2022-02-08 | — | — | CN | claimed |